Physician profile
Michael Ye
NPI 1144711581
$2,292.42
in general payments reported to CMS, 2019-2025
13 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 83% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2023: $411 · 2024: $540 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $621.35 | 2023-2025 | |
| Medtronic, INC. | $445.51 | 2024-2025 | Fusion, Propel, Nim Vital |
| Regeneron Healthcare Solutions, INC. | $305.91 | 2023-2025 | Dupixent |
| Stryker Corporation | $247.91 | 2025 | Audion Et Dilation System |
| Glaxosmithkline, LLC. | $198.78 | 2021-2025 | Nucala |
| Regeneron Pharmaceuticals, INC. | $149.06 | 2025 | Dupixent |
| Aerin Medical INC. | $123.24 | 2024-2025 | |
| Inspire Medical Systems, INC. | $81.11 | 2024 | Inspire |
| Optinose US, INC. | $68.32 | 2024-2025 | |
| Neurent Medical Limited | $19.69 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Hologic Sales and Service, LLC | $16.05 | 2025 | Coolseal Generator |
| Astrazeneca Pharmaceuticals Lp | $15.49 | 2025 | Tezspire |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.